Addex Flags Going-Concern Doubt, H1 Loss, and $2.8M ATM Lifeline
ADXN sits 20% above its 52-week low of $3.1 on light trading volume (0.1× avg).
Summary
Addex Therapeutics posted a CHF 3.5 million H1 2026 net loss, issued a going-concern warning, and raised USD 2.8 million post-period via ATM. Cash runway extends to Q4 2027, but substantial doubt remains about its ability to continue as a going concern.
Key Events · Earnings and Guidance · ADXN
-
Going-Concern Warning Disclosed
The filing states that a material uncertainty exists that raises substantial doubt about the Group's ability to continue as a going concern for one year from the issuance date.
-
H1 2026 Net Loss of CHF 3.5M
Net loss for the six months ended June 30, 2026 was CHF 3,456,418, compared to CHF 3,314,028 in the prior-year period.
-
Cash Position Deteriorates
Cash and cash equivalents fell to CHF 767,328 at June 30, 2026, from CHF 1,638,612 at December 31, 2025.
-
Post-Period ATM Raise of USD 2.8M
Between July 1 and August 25, 2026, the company sold 52,970,533 shares through its ATM facility for gross proceeds of USD 2.8 million (CHF 2.3 million).
Analysis · ADXN · Life Sciences
A CHF 3.5 million net loss for the first half of 2026 and a going-concern warning—citing material uncertainty about its ability to continue—were reported by Addex Therapeutics. Cash dwindled to CHF 0.8 million at June 30, 2026, though a post-period ATM sale raised USD 2.8 million, extending the runway to Q4 2027. The company also regained full rights to its GABAB PAM portfolio from Indivior, a positive development that nonetheless does not offset the near-term liquidity risk.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADXN was trading at $3.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $3.10 to $12.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.